News Nanexa AB

Equities

Delayed Nasdaq Stockholm Other stock markets 08:03:43 29/04/2024 pm IST			5-day change	1st Jan Change
0.612 ^SEK	+0.99%		-4.38%	-50.24%

16/04	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI
08/03	Transcript : Nanexa AB - Special Call

Nanexa invites to Capital Markets Day on May 7	03:00pm	AQ
Approval of clinical trial application for NEX-22 study delayed	16/04	AQ
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	16/04	CI
Notice of annual general meeting in Nanexa AB (publ)	15/04	AQ
Nanexa publishes annual report for 2023	27/03	AQ
Transcript : Nanexa AB - Special Call	08/03
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	22/02	AQ
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	22/02	AQ
Nanexa publishes year-end report and Q4 report 2023	21/02	AQ
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02	CI
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	20/02	AQ
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	21/12	AQ
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	20/12	AQ
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	20/12	CI
Nanexa optimizes business operations through tactical priorities	20/12	AQ
Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11	AQ
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	29/11	MT
Nanexa signs evaluation agreement with a large global pharmaceutical company	29/11	AQ
Nanexa Q3 - Focused approach	21/11	AQ
Equity Research \| NANEXA: Raising our LOAs following a review of the projects	21/11	AQ

No results for this search